Has the survival of patients with glioblastoma changed over the years?

被引:51
作者
deSouza, R. M. [1 ]
Shaweis, H. [1 ]
Han, C. [2 ]
Sivasubramiam, V. [1 ]
Brazil, L. [3 ]
Beaney, R. [3 ]
Sadler, G. [4 ]
Al-Sarraj, S. [5 ]
Hampton, T. [6 ]
Logan, J. [1 ]
Hurwitz, V. [1 ]
Bhangoo, R. [1 ]
Gullan, R. [1 ]
Ashkan, K. [1 ]
机构
[1] Kings Coll Hosp London, Dept Neurosurg, Denmark Hill, London SE5 9RS, England
[2] Univ Oxford, Canc & Haematol Ctr, Med Stat, Dept Oncol,Churchill Hosp, Oxford OX3 7LE, England
[3] Guys & St Thomas NHS Fdn Trust, Dept Clin Oncol, London SE1 9RT, England
[4] Maidstone & Tunbridge Wells NHS Trust, Kent Oncol Ctr, Dept Clin Oncol, Hermitage Lane, Maidstone ME16 9QQ, Kent, England
[5] Kings Coll Hosp London, Dept Neuropathol, Denmark Hill, London SE5 9RS, England
[6] Kings Coll Hosp London, Dept Neuroradiol, Denmark Hill, London SE5 9RS, England
关键词
glioblastoma; survival; time; neuro-oncology; POPULATION-BASED REGISTRY; RANDOMIZED PHASE-III; MALIGNANT GLIOMA; RECURRENT GLIOBLASTOMA; ADJUVANT TEMOZOLOMIDE; CLINICAL-TRIAL; SURGERY; RADIOTHERAPY; RESECTION; MGMT;
D O I
10.1038/bjc.2015.421
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Over the last decade, the approach to the management of brain tumours and the understanding of glioblastoma tumour biology has advanced and a number of therapeutic interventions have evolved, some of which have shown statistically significant effects on overall survival (OS) and progression-free survival in glioblastoma. The aim of this study is to compare survival in glioblastoma patients over a 10-year period (1999-2000 and 2009-2010). Methods: A retrospective cohort study was performed. Identification of all histologically confirmed glioblastoma in a single centre in years 1999, 2000, 2009 and 2010, and production of survival analysis comparing 1999-2000 and 2009-2010 were achieved. Results: A total of 317 patients were included in the analysis (133 in year 1999-2000, and 184 in year 2009-2010). Cox regression analysis showed that the survival was significantly longer in patients in years 2009-2010 than those in 1999-2000 at P<0.001 with HR = 0.56, confidence interval (CI) (0.45-0.71). The 1- and 3-year survival rates were 20.7% and 4.4%, respectively, for patients in 1999-2000, improving to 40.0% and 10.3%, respectively, for patients in 2009-2010. The comparisons between the two groups in survival at 1, 2 and 3 years are all statistically significant at P<0.001, respectively. The median OS was 0.36 and 0.74 in 1999-2000 and 2009-2010 groups, respectively. Conclusions: Over this period, OS from glioblastoma has increased significantly in our unit. We believe this is due to the institution of evidence-based surgical and oncological strategies practised in a multidisciplinary setting.
引用
收藏
页码:146 / 150
页数:5
相关论文
共 40 条
  • [1] [Anonymous], COCHRANE DATABASE SY
  • [2] Brain tumors in Sweden: Data from a population-based registry 1999-2012
    Asklund, Thomas
    Malmstrom, Annika
    Bergqvist, Michael
    Bjor, Ove
    Henriksson, Roger
    [J]. ACTA ONCOLOGICA, 2015, 54 (03) : 377 - 384
  • [3] Considerable improvement in survival for patients aged 60-84 years with high grade malignant gliomas - Data from the Swedish Brain Tumour Population-based Registry
    Asklund, Thomas
    Malmstrom, Annika
    Bjor, Ove
    Blomquist, Erik
    Henriksson, Roger
    [J]. ACTA ONCOLOGICA, 2013, 52 (05) : 1043 - 1046
  • [4] Heterogeneity Maintenance in Glioblastoma: A Social Network
    Bonavia, Rudy
    Inda, Maria-del-Mar
    Cavenee, Webster K.
    Furnari, Frank B.
    [J]. CANCER RESEARCH, 2011, 71 (12) : 4055 - 4060
  • [5] Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents
    Esteller, M
    Garcia-Foncillas, J
    Andion, E
    Goodman, SN
    Hidalgo, OF
    Vanaclocha, V
    Baylin, SB
    Herman, JG
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (19) : 1350 - 1354
  • [6] Evaluating the prognostic factors effective on the outcome of patients with glioblastoma multiformis: does maximal resection of the tumor lengthen the median survival?
    Faramarz-Allandini
    Amirjamshidi, Abbass
    Reza-Zarei, Mohammad
    Abdollahi, Morteza
    [J]. WORLD NEUROSURGERY, 2010, 73 (02) : 128 - 134
  • [7] Clinical trial participation and outcome for patients with glioblastoma: Multivariate analysis from a comprehensive dataset
    Field, Kathryn M.
    Drummond, Katharine J.
    Yilmaz, Merve
    Tacey, Mark
    Compston, Daniel
    Gibbs, Peter
    Rosenthal, Mark A.
    [J]. JOURNAL OF CLINICAL NEUROSCIENCE, 2013, 20 (06) : 783 - 789
  • [8] Comparison of 18F-FET PET and 5-ALA fluorescence in cerebral gliomas
    Floeth, Frank Willi
    Sabel, Michael
    Ewelt, Christian
    Stummer, Walter
    Felsberg, Jorg
    Reifenberger, Guido
    Steiger, Hans Jakob
    Stoffels, Gabriele
    Coenen, Heinz Hubert
    Langen, Karl-Josef
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 (04) : 731 - 741
  • [9] Gliobastoma multiforme and the epidermal growth factor receptor
    Friedman, HS
    Bigner, DD
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (19) : 1997 - 1999
  • [10] Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
    Gilbert, Mark R.
    Wang, Meihua
    Aldape, Kenneth D.
    Stupp, Roger
    Hegi, Monika E.
    Jaeckle, Kurt A.
    Armstrong, Terri S.
    Wefel, Jeffrey S.
    Won, Minhee
    Blumenthal, Deborah T.
    Mahajan, Anita
    Schultz, Christopher J.
    Erridge, Sara
    Baumert, Brigitta
    Hopkins, Kristen I.
    Tzuk-Shina, Tzahala
    Brown, Paul D.
    Chakravarti, Arnab
    Curran, Walter J., Jr.
    Mehta, Minesh P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (32) : 4085 - +